José Valentín
García Gutiérrez
Profesor/a Asociado/a en CC. de la Salud
Hospital Universitario Príncipe de Asturias
Alcalá de Henares, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Príncipe de Asturias (22)
2024
-
Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)
Scientific Reports
-
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
Leukemia
-
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
HemaSphere
-
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
Leukemia
-
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
American Journal of Hematology
2023
-
Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia
HemaSphere, Vol. 7, Núm. 8, pp. E936
-
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain
Annals of Hematology, Vol. 102, Núm. 2, pp. 447-456
2022
-
Breakthrough infections in MPN-COVID vaccinated patients
Blood Cancer Journal
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
-
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19
American Journal of Hematology
-
Second versus first wave of COVID-19 in patients with MPN
Leukemia
2021
-
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
Blood Cancer Journal, Vol. 11, Núm. 2
-
Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia
British Journal of Haematology, Vol. 192, Núm. 6, pp. 988-996
-
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
Leukemia, Vol. 35, Núm. 2, pp. 485-493
-
Long-term follow-up of recovered MPN patients with COVID-19
Blood Cancer Journal
2020
-
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158
2017
-
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Haematologica, Vol. 102, Núm. 1, pp. 103-109
2016
-
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Haematologica, Vol. 101, Núm. 8, pp. 926-931
-
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
British Journal of Haematology, Vol. 172, Núm. 5, pp. 786-793
2015
-
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
Annals of Hematology, Vol. 94, Núm. 6, pp. 911-918